1 / 19

Dr Saqib Mahmud MRCP(UK), MRCPS(Glasg), MRCGP

ED. Dr Saqib Mahmud MRCP(UK), MRCPS(Glasg), MRCGP. ED-inability to achieve/maintain an erection sufficient for mutually satisfying intercourse. Incidence- increase with age 39% men aged 40yrs, 67% age 70yrs

shamira
Download Presentation

Dr Saqib Mahmud MRCP(UK), MRCPS(Glasg), MRCGP

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. ED Dr Saqib Mahmud MRCP(UK), MRCPS(Glasg), MRCGP

  2. ED-inability to achieve/maintain an erection sufficient for mutually satisfying intercourse • Incidence- increase with age • 39% men aged 40yrs, 67% age 70yrs • Present worldwide prevalence>150 million men, double in next 25yrs >300 million men by 2025 • Previously thought of inorganic origin, now believed that ED is increasingly due to organic disease

  3. Mechanism of erection • Largely a vascular event • In response to sexual stimuli, parasympathetic nervous system dilates cavernosal arteries & relaxes trabecular smooth muscle increased blood flow filing sinusoidal spaces engorge penis (tumescence) compress & stops venous outflow maintaining the erection • Reverse of these events after ejaculation sympathetic activity--.contraction of arteries & trabecular smooth muscle--.venous outflow decompression of venous channels (detumescence)

  4. Chemical pathways in penile erection • Most important NO-induced cGMP pathway • Endothelial cells release NO in response to sexual stimuli • NO increases cGMP, which relaxes the corpus cavernosal smooth muscle leading to an erection • Detumescence occurs when cGMP is broken down by an enzyme ‘’phosphodiesterase’’(PDE-5)hence the role of PDE5 inhibitors in maintaining the erection

  5. causes • Vascular-endothelial dysfunction, atherosclerosis, htn, hypercholesterolemia • Endocrine-DM, hypothyroidism, hyperprolactinaemia, testosterone deficiency, hormonal imbalance due to hepatic & renal disease • Neurological-MS, CVA, Parkinson’s, Alzheimer’s, spinal cord & brain injuries • Peyronie’s disease- rare inflammatory condition->scaring of erectile tissue->painful erection

  6. Drugs->200 commonly prescribed drugs can cause or contribute to ED • Beta-blockers • Diuretics-BFZ, furosemide • ACEI • CCB • LH-RH analogs • Antiandrogens • Benzodiazepines • Alcohol • Illicit drugs

  7. Other causes of ED • Pelvic trauma • Radiotherapy • Colorectal, prostate & bladder surgery increases the risk of ED • Vascular leak- veins unable to constrict efficiently during erection • Substance abuse- chronic use of cocaine, marijuana, alcohol, steroids • Excessive use of tobacco-nicotine in tobacco causes contraction of small blood vessels less flow to the region->ED

  8. Psychological causes of ED • Depression • Anxiety • Stress • Performance anxiety– anxiety & stress lead to increased production of catecholamine which act as erection inhibitors

  9. Assessment – ED as a marker Study of 980 men with ED found; • 18% - undiagnosed HTN • 16% - DM • 15% - BPH • 5% - IHD • 4% - Ca Prostate • 1% - Depression b/w 39 & 64% of males with CVD suffer from ED

  10. Physical Assessment • BP • Femoral & peripheral pulses, femoral bruits – vascular abnormalities / PVD • Neurological exam – deep tendon reflexes, bulbocavernosis reflex (gentle squeeze of glans anal contraction), reduced sensation- sacrum, perineum • Visual field defects – prolactinoma, pituitary mass • Gynaecomastia – hyperprolactinaemia • Testicular atrophy- testosterone def, hypogonadism

  11. Assessment - contd • Rectal exam – assessment of prostate & sphincter tone • PHQ-9 Questionnaire • FBS • U&Es, LFTs, TFTs • Serum testosterone & SHBG, prolactin

  12. Management of ED • PDE5 inhibitors – sildenafil, tadalafil, vardenafil • Sildenafil (1998) - 25mg, 50mg,100mg Taken 1hr before sex, effective up to 4 to 5 hrs, s/e - headache • Tadalafil (2003) – 10mg, 20mg(PRN) 2.5mg, 5mg(once daily-2009) Taken 30 minutes before sex, effective up to 36hrs, s/e - dyspepsia, headache

  13. contd • Vardenafil(2003) – 5mg, 10mg, 20mg Taken 25 – 60minutes before sex, effective up to 4 – 5 hrs, s/e – headache, flushing

  14. When PDE5 inhibitors don’t work Patient Education • 81% do not take them correctly • Adequate sexual stimulation necessary • Food & alcohol delay & reduce absorption • Some need 6-8 doses before an optimal response occurs • Psychotherapy integrated with pharmacotherapy

  15. Prescribing advice • Switch drugs • Optimize dose – increase to max • Patients unresponsive to PRN Tadalafil, consider once daily regime • Combine with other drugs; intraurethral alprostadil with PDE5 inhibitors or with doxazocin (weak erectogenic agent) ideal with BPH+HTN patients

  16. Other treatments for ED • MUSE – medicated urethral system for erection, pallet of PGE1(alprostadil) inserted in urethra 15min before sex, lasts 30 to 60min • Can be used up to twice daily • s/e – penile pain, burning (32%) • 43% efficacy compared to intracavernosal route but less complications such as priapism and penile fibrosis with injections

  17. Vacuum constriction devices • SOMACorrect Xtra, SOMAerect Response II • One time cost (£160 - £180/-) • Efficacy – 92% regardless of underlying cause of ED • Time to erection onset- 90 to 120 seconds • Time required to terminate erectin <30seconds • No systemic side effects compared to oral Rx

  18. Surgical treatment for ED • Penile prosthesis – for patients who probabaly have sufffered physical damage to corpora, renndering other treatments ineffective • Vascular surgery – when ED is due to poor arterial inflow or abnormal venous drainage ( arterial revascularization, ligation of venous incompetence) • Results vary widely but usually poor

  19. Testosterone therapy • Only indicated in men whose loss of libido/ ED is due to hypogonadism or documented low testosterone levels • Testosterone deficiency is a rare cause of ED • Administered orally, i/m injections, skin patches or implants

More Related